Abstracts tagged "Disease Activity"

Abstract Number: 2654 • ACR Convergence 2025
Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis
Ellen Romich¹, Alexis Ogdie², Alisa Stephens Shields², Peter Merkel², Jessica Alvey³, Shervin Assassi⁴, Elana Bernstein⁵, Sonali Bracken⁶, Flavia Castelino⁷, Lorinda Chung⁸, Luke Evnin⁹, Tracy Frech¹⁰, Jessica Gordon¹¹, Faye Hant¹², Monica Harding¹³, Laura Hummers¹⁴, Dinesh Khanna¹⁵, Kimberly Lakin¹¹, Dorota Lebiedz-Odrobina¹³, Yiming Luo⁵, Ashima Makol¹⁶, Maureen Mayes¹⁷, Zsuzsanna McMahan¹⁸, Jerry Molitor¹⁹, Duncan Moore²⁰, Carrie Richardson²¹, Ami Shah¹⁴, Ankoor Shah²², Brian Skaug²³, Virginia Steen²⁴, John VanBuren¹³, Elizabeth Volkmann²⁵, Carleigh Zahn¹⁵ and Nora Sandorfi², ¹University of Pennsylvania, Media, PA, ²University of Pennsylvania, Philadelphia, PA, ³Utah Data Coordinating Center, University of Utah, Salt Lake City, UT, ⁴Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁵Columbia University, New York, NY, ⁶Duke University Medical Center, Durham, NC, USA, Apex, NC, ⁷Massachusetts General Hospital, Boston, MA, ⁸Stanford University, Stanford, CA, ⁹Scleroderma Research Foundation, San Francisco, CA, ¹⁰Vanderbilt University Medical Center, Nashville, TN, ¹¹Hospital for Special Surgery, New York, NY, ¹²Medical University of South Carolina, Charleston, SC, ¹³University of Utah, Salt Lake City, UT, ¹⁴Johns Hopkins Rheumatology, Baltimore, MD, ¹⁵University of Michigan, Ann Arbor, MI, ¹⁶Mayo Clinic, Rochester, MN, ¹⁷UT Health Houston Division of Rheumatology, Houston, TX, ¹⁸UT Health Houston, Houston, TX, ¹⁹University of Minnesota, Minneapolis, MN, ²⁰Northwestern Memorial Hospital, Chicago, IL, ²¹Northwestern University, Chicago, IL, ²²Duke University, Durham, NC, ²³UTHealth Houston Division of Rheumatology, Houston, TX, ²⁴Georgetown University School of Medicine, Washington, DC, ²⁵Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: To determine the frequency and extent of discordance between patient and physician global assessments of disease in early systemic sclerosis and identify factors associated…
Abstract Number: 2347 • ACR Convergence 2025
Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension
Fabian Proft¹, Désirée Van Der Heijde², Sergio Schwartzman³, Vanessa Taieb⁴, Sarah Kavanagh⁵, Gaëlle Varkas⁶, Victoria Navarro-Compan⁷ and Xenofon Baraliakos⁸, ¹Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Weill Cornell Medical Center, New York Presbyterian Hospital, and Hospital for Special Surgery, New York, NY, ⁴UCB, Colombes, France, ⁵UCB, Morrisville, NC, ⁶Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁷Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which requires optimal management.1 In clinical trials, Assessment of SpondyloArthritis international Society ≥40% improvement (ASAS40) is…
Abstract Number: 2131 • ACR Convergence 2025
Transition from Juvenile Dermatomyositis to Spondyloarthritis: A Novel Overlapping Inflammatory Phenotype
Austen Grooms¹, Ioannis Karageorgiou², Kerry Mychaliska² and James Birmingham³, ¹William Beaumont University Hospital, Auburn Hills, MI, ²William Beaumont University Hospital, Royal Oak, MI, ³River City Rheumatology, Grand Rapids, MI
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare inflammatory disease primarily affecting muscle, skin, and vasculature. Characterized by muscle weakness, distinctive skin lesions, and autoantibodies, it…
Abstract Number: 1550 • ACR Convergence 2025
Real-World Outcomes of Anifrolumab in Systemic Lupus Erythematosus Patients at Toronto Lupus Program
Virginia Carrizo Abarza¹, Qixuan Li², Teresa Semalulu³, Justin Smith³, Pankti Mehta⁴, Fadi Kharouf⁵, Dafna D. Gladman⁶, Laura Whitall Garcia⁷ and Zahi Touma³, ¹Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁵University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody targeting the type I interferon receptor subunit 1 (IFNAR1), blocking interferon activity and reducing disease activity in…
Abstract Number: 1409 • ACR Convergence 2025
The impact of depression in axial spondyloarthritis: Epidemiological insights from the Ankylosing Spondylitis Registry of Ireland (ASRI)
Conall Mac Gearailt¹, Rebecca O'Farrell², Mohamed Eltahir³, Brian Hallahan³, Andrew Smyth⁴, Finbar O'Shea⁵ and Gillian Fitzgerald³, ¹Galway University Hospital, Galway, Galway, Ireland, ²Sligo University Hospital, Sligo, Ireland, ³Galway University Hospital, Galway, Ireland, ⁴University of Galway, Galway, Ireland, ⁵St James's Hospital and Trinity College Dublin, Dublin, Dublin, Ireland
Background/Purpose: The burden of comorbidities in Axial Spondyloarthritis (axSpA) is increasingly recognised and contributes to the concept of difficult-to-treat axSpA (D2T-axSpA). The need to assess…
Abstract Number: 1207 • ACR Convergence 2025
Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis
Jesus Valencia¹, Will Kelly¹, Sean Tackett², Amanda Finney¹, Jemima Albayda¹, Julie Paik³, Lisa Christopher-Stine¹ and Chris Mecoli⁴, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease characterized by cutaneous manifestations and proximal muscle inflammation.1,2 Notably, the clinical course of muscular and cutaneous disease…
Abstract Number: 0874 • ACR Convergence 2025
Impact of Deucravacitinib on Disease Activity in Patients With Psoriatic Arthritis (PsA): Results From the Pivotal Phase 3 PsA Studies
Atul Deodhar¹, Ricardo Blanco², Arthur Kavanaugh³, Alice Gottlieb⁴, Laura Coates⁵, Christopher Ritchlin⁶, Alan Kivitz⁷, Xiaofeng Zeng⁸, Akimichi Morita⁹, Diamant Thaçi¹⁰, Stefan Varga¹¹, Kexuan Li¹¹, Ying-Ming Jou¹², Eleni Vritzali¹³ and Philip J. Mease¹⁴, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³University of California, San Diego, School of Medicine, San Diego, CA, ⁴Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁶University of Rochester Medical Center, Canandaigua, NY, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ⁹Department of Geriatric and Environmental Dermatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan, ¹⁰Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ¹¹Bristol Myers Squibb, Princeton, NJ, ¹²Bristol Myers Squibb, Princeton, ¹³Bristol Myers Squibb, Boudry, Switzerland, ¹⁴Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: The first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has an established clinical profile in moderate to severe plaque psoriasis with over…
Abstract Number: 0480 • ACR Convergence 2025
Efficacy and safety of tacrolimus and its serum concentration in patients with rheumatoid arthritis with inadequate response to methotrexate
Chan-Bum Choi, Hanyang University Hosptial for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Addition of a biologic disease-modifying antirheumatic drug (bDMARD) or targeted synthetic DMARD (tsDMARD) is recommended in patients with rheumatoid arthritis (RA) with inadequate response…
Abstract Number: 0297 • ACR Convergence 2025
Longitudinal Serum Proteomic Profiles – A Step Closer to Personalized Monitoring in Dermatomyositis
Natasha Le Blanc¹, Marie Hudson¹, Ana Cristina Gonzalez Sanchez², Lina Marcela Diaz Gallo² and Valerie Leclair³, ¹McGill University, Montréal, QC, Canada, ²Karolinska Institutet, Stockholm, Sweden, ³McGill University, Montréal, Canada
Background/Purpose: Dermatomyositis (DM) is a multisystemic immune mediated disease presenting with heterogeneous clinical features. Disease monitoring in DM relies in part on biomarkers of muscle…
Abstract Number: 2650 • ACR Convergence 2025
LFA-REAL Outperforms SLEDAI and BILAG in Detecting Clinical Change in Lupus Activity
Alberto Nordmann-Gomes¹, Leila Khalili², Cynthia Aranow³, Meghan mackay⁴, Mimi Kim⁵, Diane Kamen⁶, Cristina Arriens⁷, Maya Souvignier⁸, Wei Tang⁹, Stephen Suh⁸, Maria Dall'Era¹⁰, Joan Merrill¹¹ and Anca Askanase², ¹Columbia University Irving Medical Center, New York, NY, ²Columbia University Medical Center, New York, NY, ³Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Feinstein Institutes for Medical Research, Manhasset, NY, ⁵Albert Einstein College of Medicine, Bronx, NY, ⁶Medical University of South Carolina, Johns Island, SC, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Columbia University Irving Medical Center, New York City, NY, ⁹Westchester Medical Center, Valhalla, NY, ¹⁰Division of Rheumatology, University of California, San Francisco, CA, ¹¹Oklahoma Medical Research Foundation, Oklahoma
Background/Purpose: Disease activity measures in SLE have important limitations that restrict their performance in clinical practice and research. The Lupus Foundation of America-Rapid Evaluation of…
Abstract Number: 2332 • ACR Convergence 2025
Development and validation of a Disease Activity index for PSoriatic Arthritis based on 44 joints: DAPSA44
Dafne capelusnik¹, Clementina López Medina², Désirée Van Der Heijde³, Daniel Aletaha⁴, Josef Smolen⁵, Anna Molto⁶ and Sofia Ramiro⁷, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Medical University Vienna, Wien, Austria, ⁵Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁶Assistance Publique Hôpitauxde Paris, Paris, France, ⁷Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Recent studies have highlighted the potential of composite scores such as the DAPSA for assessing peripheral arthritis in axSpA and pSpA. However, the swollen…
Abstract Number: 2124 • ACR Convergence 2025
Reliability and Validation of the Physician’s Global Assessment of Lung Disease (PGALD) in Systemic Juvenile Idiopathic Arthritis -Associated Lung Disease (SJIA-LD)
Eileen Rife¹, Guihua Zhai², Mekibib Altaye³, Jennifer Andringa⁴, Hermine Brunner⁵, Scott Canna⁶, Lauren Henderson⁷, Yukiko Kimura⁸, Scott Lieberman⁹, Mona Riskalla¹⁰, Tiphanie Vogel¹¹, Holly Wobma¹² and Grant Schulert⁵, ¹University of Alabama at Birmingham, birmingham, AL, ²UAB, Birmingham, ³Cincinnati Children's Hospital, Cincinnati, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Children's Hospital of Philadelphia, Philadelphia, PA, ⁷Boston Children's Hospital, Watertown, MA, ⁸Hackensack Meridian School of Medicine, New York, NY, ⁹University of Iowa, Iowa City, IA, ¹⁰University of Minnesota Masonic Children's Hospital, Minneapolis, MN, ¹¹Baylor College of Medicine, Houston, TX, ¹²Boston Children's Hospital, Boston, MA
Background/Purpose: The physician global assessment of lung disease (PGALD) is a recently proposed disease activity measure for patients with systemic juvenile idiopathic arthritis-associated lung disease…
Abstract Number: 1536 • ACR Convergence 2025
Evaluating Systemic Lupus Erythematosus Remission Among Patients Initiating Belimumab in a Real-World Setting in the USA
Aarat M Patel¹, Renee L. Gennarelli², Temitope Bello², Ali Bonakdar² and Karen Worley³, ¹GSK, US Medical Affairs, Durham, NC, ²Cencora, Real-World Evidence, Conshohocken, PA, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA
Background/Purpose: The Definition Of Remission In SLE (DORIS) criteria were developed to provide alignment on defining remission in patients with SLE.1,2 Belimumab (BEL) treatment increases…
Abstract Number: 1396 • ACR Convergence 2025
Influence of Age on Daily Impairment, Patient Empowerment, Activation and Engagement in Patients with Sjögren’s Disease
Esra Sevimli¹, Berceste Polat², Busra Sari³, Can Akmansoy², Burcu Aksoy⁴, Omur Mumcu⁵, Hatice Kalender³, Aysegul Avcu⁶, Mustafa Erdogan⁷, Nur Sisman⁸, Farida Fortune⁹, Gonca Mumcu¹⁰ and Nevsun Inanc⁷, ¹¹Institute of Health Sciences, Marmara University, Department of Health Management, Istanbul, Turkey, ²Marmara University, Faculty of Dentistry, Istanbul, Turkey, ³Institute of Health Sciences, Marmara University, Department of Health Management, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Institute of Postgraduate Education, Department of Health Management, Istanbul, Turkey, ⁵Yeditepe University, Faculty of Dentistry, Istanbul, Turkey, ⁶Marmara University, Istanbul, Turkey, ⁷Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁸Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁹Barts and The London School of Medicine and Dentistry, Centre Immunobiology and Regenerative Medicine, Queen Mary University of London, London, United Kingdom, ¹⁰Faculty of Dentistry, Istanbul Okan University, Istanbul, Turkey
Background/Purpose: Patient-centred care and improvement of daily life are the main components in chronic disease management. The aim of the study was to determine associations…
Abstract Number: 1159 • ACR Convergence 2025
IL-18 Correlates with Pouchot Score and Inflammatory Biomarkers in Adult-Onset Still’s Disease: Insights From a Repeated Measures Study
Hadeel Abdul-Rehman¹, Karen Gambina² and Bella Mehta³, ¹Hospital for Special Surgery, New York, NY, ²Columbia University Medical Center, Islip, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Adult-Onset Still’s Disease (AOSD) is a rare systemic inflammatory disease. Interleukin-18 (IL-18) levels are significantly elevated in AOSD patients¹ and may be a promising…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].